Peptide injection sites: what TikTok gets right and wrong

What did @kaykirajyan actually say?

The creator recommended injecting peptides "subcutaneously" into the lower stomach or glutes, arguing that injecting "wherever you have the most body fat" tends to hurt less. She also mentioned she follows a five-days-on, two-days-off dosing schedule and closed with the take that "stomach, glutes, thigh, it all works." That last part is actually the most defensible thing she said.

To be fair, she is not making outlandish medical claims here. This is practical injection guidance from a personal-use perspective, not a clinical protocol. But "it all works" glosses over real differences in peptide pharmacokinetics depending on the compound and the injection route, which matter more than pain preference alone.

Does the science back this up?

Mostly, yes, with some important caveats. Subcutaneous injection is the standard route for most research peptides, and there is reasonable pharmacokinetic justification for it. The claim that body fat correlates with lower injection pain also has support.

Subcutaneous administration produces slower, more consistent absorption compared to intramuscular injection for many peptide compounds. A 2004 review by Hillery and Lloyd in Drug Delivery and Targeting established that subcutaneous tissue acts as a depot, extending the absorption window for peptide drugs. This is particularly relevant for growth hormone secretagogues like CJC-1295 and ipamorelin, where a gradual release profile is generally preferred over a sharp spike.

Pain reduction in fattier tissue is also biologically plausible. Adipose tissue has a lower density of pain receptors compared to muscle, and the needle does not need to penetrate fascia. However, injecting too deep into muscle when targeting subcutaneous tissue, especially in lean individuals, can alter absorption kinetics in ways the creator does not mention.

What did they get wrong (or right)?

She got the basics right. She got the nuance wrong by omission. The claim that intramuscular injection is simply "ow" and subcutaneous is smoother is a personal preference framed as universal fact. For some peptides, route of administration is not purely a comfort decision.

TB-500, for example, has been studied primarily via intraperitoneal and intramuscular routes in animal models (Goldstein et al., 2012, Annals of the New York Academy of Sciences). Extrapolating subcutaneous preference to every peptide without acknowledging compound-specific data is a real gap. BPC-157, similarly, has most of its animal-model evidence from oral or intraperitoneal administration, not subcutaneous.

The five-days-on, two-days-off cycling claim is presented without any explanation or citation. This is a widely repeated protocol in online peptide communities but has essentially no published clinical basis for most of the peptides in this category. Presenting it as a clean conclusion without context is misleading by implication.

What should you actually know?

If you are using peptides under medical supervision, injection site guidance should come from a licensed prescriber who knows the specific compound, your body composition, and your goals. General advice about "wherever is less painful" is not wrong, but it is incomplete.

A few things worth knowing that the video skips entirely. First, site rotation matters. Repeated injections into the same location, especially the lower abdomen, can cause lipodystrophy, a localized breakdown or buildup of fat tissue. This is well-documented in insulin users (Gentile et al., 2016, Diabetes Technology and Therapeutics) and relevant to anyone doing frequent subcutaneous injections. Second, needle length and gauge affect whether you actually hit subcutaneous tissue versus muscle, particularly in leaner individuals. Third, sterile technique is not mentioned at all in this video. The injection site matters far less than whether you are using proper aseptic protocol.

The creator's instinct toward subcutaneous injection for most peptides is defensible. The packaging of it as universal, painless, and interchangeable across all peptides is where the video oversimplifies.

Bottom line

This video is low-harm, general guidance that gets the fundamentals right but leaves out enough clinical context to matter. Subcutaneous injection is appropriate for most peptide compounds. Rotating sites, using proper sterile technique, and understanding that route of administration can affect pharmacokinetics are things your prescriber should cover, and this video does not.